Review



ace2  (BPS Bioscience)


Bioz Verified Symbol BPS Bioscience is a verified supplier
Bioz Manufacturer Symbol BPS Bioscience manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    BPS Bioscience ace2
    DMA-β-CyD acts directly on SARS-CoV-2 and reduces its infectivity titer. DMA-β-CyD was directly exposed to different SARS-CoV-2 variants for ( A ) 10 min and ( B ) 180 min. Viral infectivity titers were expressed in TCID 50 /mL, and significant differences (Student’s t -test) are indicated in the figures. Mean values from at least three independent experiments are shown, and error bars indicate SD. ( C ) Competitive inhibition experiment with DMA-β-CyD. Recombinant <t>ACE2</t> was used, and DMA-β-CyD was pre-incubated before the loading of the recombinant spike protein. Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Dunnett’s test. n.s. indicates not significant. The mean values of at least three independent experiments are shown. The error bars denote SD.
    Ace2, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+hek293+recombinant+cell+line/ACE2+-+HEK293+Recombinant+Cell+Line/pmc12724303-134-13-22
    Average 94 stars, based on 27 article reviews
    ace2 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "Targeting envelope lipids with 2,6‑di‑ O ‑methyl‑3‑acetyl‑β‑cyclodextrin impairs infectivity of SARS‑CoV‑2 and Japanese encephalitis virus"

    Article Title: Targeting envelope lipids with 2,6‑di‑ O ‑methyl‑3‑acetyl‑β‑cyclodextrin impairs infectivity of SARS‑CoV‑2 and Japanese encephalitis virus

    Journal: Journal of Virology

    doi: 10.1128/jvi.01357-25

    DMA-β-CyD acts directly on SARS-CoV-2 and reduces its infectivity titer. DMA-β-CyD was directly exposed to different SARS-CoV-2 variants for ( A ) 10 min and ( B ) 180 min. Viral infectivity titers were expressed in TCID 50 /mL, and significant differences (Student’s t -test) are indicated in the figures. Mean values from at least three independent experiments are shown, and error bars indicate SD. ( C ) Competitive inhibition experiment with DMA-β-CyD. Recombinant ACE2 was used, and DMA-β-CyD was pre-incubated before the loading of the recombinant spike protein. Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Dunnett’s test. n.s. indicates not significant. The mean values of at least three independent experiments are shown. The error bars denote SD.
    Figure Legend Snippet: DMA-β-CyD acts directly on SARS-CoV-2 and reduces its infectivity titer. DMA-β-CyD was directly exposed to different SARS-CoV-2 variants for ( A ) 10 min and ( B ) 180 min. Viral infectivity titers were expressed in TCID 50 /mL, and significant differences (Student’s t -test) are indicated in the figures. Mean values from at least three independent experiments are shown, and error bars indicate SD. ( C ) Competitive inhibition experiment with DMA-β-CyD. Recombinant ACE2 was used, and DMA-β-CyD was pre-incubated before the loading of the recombinant spike protein. Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Dunnett’s test. n.s. indicates not significant. The mean values of at least three independent experiments are shown. The error bars denote SD.

    Techniques Used: Infection, Inhibition, Recombinant, Incubation

    DMA-β-CyD prolongs the virus-induced reduction in clotting time in human serum by masking aminophospholipids in the viral lipid envelope. ( A ) The Wuhan, Beta, and Delta variants prepared in Vero E6/TMPRSS2 cells were treated with DMA-β-CyD for the indicated times, followed by a clotting assay. ( B ) The Wuhan variant, prepared in A549 cells overexpressing ACE2, was treated with DMA-β-CyD for the indicated times, followed by a clotting assay. ( C ) To examine the significance of the molecular encapsulation activity of DMA-β-CyD, pretreatment with 10 mM DMAβCyD with equimolar (10 mM) 1adamantanecarboxylic acid was performed to assess its effect on the virus-induced reduction in clotting time. ( D ) The Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with DM-β-CyD for the indicated times, followed by a clotting assay. P values were determined using one-way ANOVA (Dunnett’s test). * indicates a statistically significant difference in clotting time between groups untreated and treated with DMA-β-CyD or DM-β-CyD ( P < 0.05). Data represent the means of at least three independent experiments, and error bars indicate SD.
    Figure Legend Snippet: DMA-β-CyD prolongs the virus-induced reduction in clotting time in human serum by masking aminophospholipids in the viral lipid envelope. ( A ) The Wuhan, Beta, and Delta variants prepared in Vero E6/TMPRSS2 cells were treated with DMA-β-CyD for the indicated times, followed by a clotting assay. ( B ) The Wuhan variant, prepared in A549 cells overexpressing ACE2, was treated with DMA-β-CyD for the indicated times, followed by a clotting assay. ( C ) To examine the significance of the molecular encapsulation activity of DMA-β-CyD, pretreatment with 10 mM DMAβCyD with equimolar (10 mM) 1adamantanecarboxylic acid was performed to assess its effect on the virus-induced reduction in clotting time. ( D ) The Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with DM-β-CyD for the indicated times, followed by a clotting assay. P values were determined using one-way ANOVA (Dunnett’s test). * indicates a statistically significant difference in clotting time between groups untreated and treated with DMA-β-CyD or DM-β-CyD ( P < 0.05). Data represent the means of at least three independent experiments, and error bars indicate SD.

    Techniques Used: Virus, Coagulation, Variant Assay, Encapsulation, Activity Assay

    Inhibition of viral entry by DMA-β-CyD and evaluation of viral particle stability. ( A ) DMA-β-CyD was preincubated with the SARS-CoV-2 Wuhan variant, which was prepared in Vero E6/TMPRSS2 cells. Free DMA-β-CyD was removed by gel filtration, and the resulting viral particles were then used to infect cells. Four hours after infection, total RNA was extracted from Vero E6/TMPRSS2 cells, and gRNA was detected by RT-PCR. P values were determined by one-way ANOVA using Dunnett’s test (** P < 0.01). N.D. indicates that the SARS-CoV-2 phenotypic RNA (gRNA) was not detected. Data represent the means of at least three independent experiments, and error bars indicate SD. ( B ) DMA-β-CyD was preincubated with the SARS-CoV-2 Wuhan variant, which was prepared in A549 cells overexpressing ACE2. The efficiency of viral entry was similarly examined. Western blot analysis results, shown in the bar graph inset, confirm ACE2 expression in A549 cells. ( C ) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with anti-SARS-CoV-2 patient serum or DMA-β-CyD for 180 min, followed by virus purification by ultracentrifugation and western blot analysis using patient antiserum. ( D ) Evaluation of virus particle stability. (Left panel) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with an anti-S2 antibody and then subjected to gel filtration. Gel filtration was also performed using mouse IgG and IgM as molecular weight markers. The resulting flow-through fraction was analyzed by western blot analysis. (Right panel) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with DMA-β-CyD or anti-SARS-CoV-2 serum. The virus was purified by gel filtration, captured on a plate coated with anti-RBD antibodies, and the number of plate-bound viral particles was quantified by RT-qPCR. P values were determined by one-way ANOVA using Dunnett’s test (** P < 0.01). N.D. indicates that no detectable SARS-CoV-2 gRNA was found. Data represent the means of at least three independent experiments, and error bars indicate SD.
    Figure Legend Snippet: Inhibition of viral entry by DMA-β-CyD and evaluation of viral particle stability. ( A ) DMA-β-CyD was preincubated with the SARS-CoV-2 Wuhan variant, which was prepared in Vero E6/TMPRSS2 cells. Free DMA-β-CyD was removed by gel filtration, and the resulting viral particles were then used to infect cells. Four hours after infection, total RNA was extracted from Vero E6/TMPRSS2 cells, and gRNA was detected by RT-PCR. P values were determined by one-way ANOVA using Dunnett’s test (** P < 0.01). N.D. indicates that the SARS-CoV-2 phenotypic RNA (gRNA) was not detected. Data represent the means of at least three independent experiments, and error bars indicate SD. ( B ) DMA-β-CyD was preincubated with the SARS-CoV-2 Wuhan variant, which was prepared in A549 cells overexpressing ACE2. The efficiency of viral entry was similarly examined. Western blot analysis results, shown in the bar graph inset, confirm ACE2 expression in A549 cells. ( C ) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with anti-SARS-CoV-2 patient serum or DMA-β-CyD for 180 min, followed by virus purification by ultracentrifugation and western blot analysis using patient antiserum. ( D ) Evaluation of virus particle stability. (Left panel) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with an anti-S2 antibody and then subjected to gel filtration. Gel filtration was also performed using mouse IgG and IgM as molecular weight markers. The resulting flow-through fraction was analyzed by western blot analysis. (Right panel) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with DMA-β-CyD or anti-SARS-CoV-2 serum. The virus was purified by gel filtration, captured on a plate coated with anti-RBD antibodies, and the number of plate-bound viral particles was quantified by RT-qPCR. P values were determined by one-way ANOVA using Dunnett’s test (** P < 0.01). N.D. indicates that no detectable SARS-CoV-2 gRNA was found. Data represent the means of at least three independent experiments, and error bars indicate SD.

    Techniques Used: Inhibition, Variant Assay, Filtration, Infection, Reverse Transcription Polymerase Chain Reaction, Western Blot, Expressing, Virus, Purification, Molecular Weight, Quantitative RT-PCR

    Related Articles

    Recombinant:

    Article Title: Chemically Synthesized 1,2,3,4,6-Pentakis-O-Galloyl-β-D-Glucopyranoside Blocks SARS-CoV-2 Spike Interaction with Host ACE-2 Receptor
    Article Snippet: .. The Spike (SARS-CoV-2) Pseudotyped Lentivirus, ACE2-HEK293 recombinant cell line, growth medium 1N, thaw medium 1, spike S1 neutralizing antibody (Clone#G10xA1), 96-well tissue culture treated, white clear-bottom assay plate, and one-step TM luciferase assay system were all procured from BPS Bioscience (San Diego, CA). ..

    Article Title: Peptides Derived from the SARS-CoV-2 S2-Protein Heptad-Repeat-2 Inhibit Pseudoviral Fusion at Micromolar Concentrations: The Role of Palmitic Acid Conjugation
    Article Snippet: .. The SARS-CoV2-spike pseudovirus and the ACE2-HEK293 recombinant cell line were prepared in-house by BPS Bioscience (San Diego, CA, USA) (#79942 and #79951, respectively). .. The MEM medium (#SH30024.01), Na-pyruvate (#SH30239.01) and Pen-strep (#SV30010) were obtained from Hyclone (Cytiva, Marlborough, MA, USA).

    Article Title: Major royal jelly proteins elicited suppression of SARS-CoV-2 entry and replication with halting lung injury
    Article Snippet: .. The ACE2-HEK293 recombinant cell line (#79951) was supplied by BPS Bioscience, San Diego, CA92121. .. The cells were maintained in growth medium 1 N (BPS Bioscience #79801): MEM (Minimum Essential Medium) medium with 10 % fetal bovine serum (FBS), 1 % non-essential amino acid, 1 mM Na-pyruvate, 1 % Pen-strep, and 0.5 μg/ml Puromycin.

    Article Title: The vaccinia‐based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses
    Article Snippet: MC57G cells (ATCC CRL‐2295; ATCC, Virginia, USA) were maintained in Eagle’s Minimum Essential Medium (Sigma Aldrich, MO, USA) supplemented with 10% fetal bovine serum, 2 m m l ‐glutamine and penicillin–streptomycin. .. ACE2‐HEK293 recombinant cell line (catalog number 79951; BPS Bioscience, San Diego, CA, USA) was maintained in Dulbecco’s Modified Eagle Medium supplemented (Sigma Aldrich, MO, USA) with 10% fetal bovine serum, 2 mM l ‐glutamine and penicillin–streptomycin. .. All cell culture reagents were purchased from Thermo Fisher Scientific, Waltham, MA, USA, unless otherwise specified.

    Article Title: The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.
    Article Snippet: MC57G cells (ATCC CRL-2295; ATCC, Virginia, USA) were maintained in Eagle’s Minimum Essential Medium (Sigma Aldrich, MO, USA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and penicillin– streptomycin. .. ACE2-HEK293 recombinant cell line (catalog number 79951; BPS Bioscience, San Diego, CA, USA) was maintained in Dulbecco’s Modified Eagle Medium supplemented (Sigma Aldrich, MO, USA) with 10% fetal bovine serum, 2 mM L-glutamine and penicillin–streptomycin. .. All cell culture reagents were purchased from Thermo Fisher Scientific, Waltham, MA, USA, unless otherwise specified.

    Article Title: A peptide derived from the SARS-CoV-2 S2-protein heptad-repeat-2 inhibits pseudoviral fusion at micromolar concentrations: Role of palmitic acid conjugation
    Article Snippet: .. The SARS-CoV2-Spike Pseudovirus and the ACE2-HEK293 Recombinant Cell Line were prepared in-house by BPS Bioscience; #79942 and, #79951, respectively) MEM medium (#SH30024.01), Na-pyruvate (#SH30239.01) and Pen-strep (#SV30010) were from Hyclone. .. Fetal bovine serum was obtained from Life Technologies (#10082147).

    Article Title: Major royal jelly proteins elicited suppression of SARS-CoV-2 entry and replication with halting lung injury.
    Article Snippet: .. The ACE2-HEK293 recombinant cell line (#79951) was supplied by BPS Bioscience, San Diego, CA92121. .. The cells were maintained in growth medium 1 N (BPS Bioscience #79801): MEM (Minimum Essential Medium) medium with 10 % fetal bovine serum (FBS), 1 % nonessential amino acid, 1 mM Na-pyruvate, 1 % Pen-strep, and 0.5 μg/ ml Puromycin.

    Luciferase:

    Article Title: Chemically Synthesized 1,2,3,4,6-Pentakis-O-Galloyl-β-D-Glucopyranoside Blocks SARS-CoV-2 Spike Interaction with Host ACE-2 Receptor
    Article Snippet: .. The Spike (SARS-CoV-2) Pseudotyped Lentivirus, ACE2-HEK293 recombinant cell line, growth medium 1N, thaw medium 1, spike S1 neutralizing antibody (Clone#G10xA1), 96-well tissue culture treated, white clear-bottom assay plate, and one-step TM luciferase assay system were all procured from BPS Bioscience (San Diego, CA). ..

    Modification:

    Article Title: The vaccinia‐based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses
    Article Snippet: MC57G cells (ATCC CRL‐2295; ATCC, Virginia, USA) were maintained in Eagle’s Minimum Essential Medium (Sigma Aldrich, MO, USA) supplemented with 10% fetal bovine serum, 2 m m l ‐glutamine and penicillin–streptomycin. .. ACE2‐HEK293 recombinant cell line (catalog number 79951; BPS Bioscience, San Diego, CA, USA) was maintained in Dulbecco’s Modified Eagle Medium supplemented (Sigma Aldrich, MO, USA) with 10% fetal bovine serum, 2 mM l ‐glutamine and penicillin–streptomycin. .. All cell culture reagents were purchased from Thermo Fisher Scientific, Waltham, MA, USA, unless otherwise specified.

    Article Title: The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.
    Article Snippet: MC57G cells (ATCC CRL-2295; ATCC, Virginia, USA) were maintained in Eagle’s Minimum Essential Medium (Sigma Aldrich, MO, USA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and penicillin– streptomycin. .. ACE2-HEK293 recombinant cell line (catalog number 79951; BPS Bioscience, San Diego, CA, USA) was maintained in Dulbecco’s Modified Eagle Medium supplemented (Sigma Aldrich, MO, USA) with 10% fetal bovine serum, 2 mM L-glutamine and penicillin–streptomycin. .. All cell culture reagents were purchased from Thermo Fisher Scientific, Waltham, MA, USA, unless otherwise specified.



    Similar Products

    ace2  (BPS Bioscience)
    94
    BPS Bioscience ace2
    DMA-β-CyD acts directly on SARS-CoV-2 and reduces its infectivity titer. DMA-β-CyD was directly exposed to different SARS-CoV-2 variants for ( A ) 10 min and ( B ) 180 min. Viral infectivity titers were expressed in TCID 50 /mL, and significant differences (Student’s t -test) are indicated in the figures. Mean values from at least three independent experiments are shown, and error bars indicate SD. ( C ) Competitive inhibition experiment with DMA-β-CyD. Recombinant <t>ACE2</t> was used, and DMA-β-CyD was pre-incubated before the loading of the recombinant spike protein. Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Dunnett’s test. n.s. indicates not significant. The mean values of at least three independent experiments are shown. The error bars denote SD.
    Ace2, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+hek293+recombinant+cell+line/ACE2+-+HEK293+Recombinant+Cell+Line/pmc12724303-134-13-22
    Average 94 stars, based on 1 article reviews
    ace2 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    ace2 hek293 recombinant cell line  (BPS Bioscience)
    94
    BPS Bioscience ace2 hek293 recombinant cell line
    DMA-β-CyD acts directly on SARS-CoV-2 and reduces its infectivity titer. DMA-β-CyD was directly exposed to different SARS-CoV-2 variants for ( A ) 10 min and ( B ) 180 min. Viral infectivity titers were expressed in TCID 50 /mL, and significant differences (Student’s t -test) are indicated in the figures. Mean values from at least three independent experiments are shown, and error bars indicate SD. ( C ) Competitive inhibition experiment with DMA-β-CyD. Recombinant <t>ACE2</t> was used, and DMA-β-CyD was pre-incubated before the loading of the recombinant spike protein. Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Dunnett’s test. n.s. indicates not significant. The mean values of at least three independent experiments are shown. The error bars denote SD.
    Ace2 Hek293 Recombinant Cell Line, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+hek293+recombinant+cell+line/ACE2+-+HEK293+Recombinant+Cell+Line/pmc11974267-147-5-38
    Average 94 stars, based on 1 article reviews
    ace2 hek293 recombinant cell line - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    hek 293t ace2 cells  (BPS Bioscience)
    94
    BPS Bioscience hek 293t ace2 cells
    DMA-β-CyD acts directly on SARS-CoV-2 and reduces its infectivity titer. DMA-β-CyD was directly exposed to different SARS-CoV-2 variants for ( A ) 10 min and ( B ) 180 min. Viral infectivity titers were expressed in TCID 50 /mL, and significant differences (Student’s t -test) are indicated in the figures. Mean values from at least three independent experiments are shown, and error bars indicate SD. ( C ) Competitive inhibition experiment with DMA-β-CyD. Recombinant <t>ACE2</t> was used, and DMA-β-CyD was pre-incubated before the loading of the recombinant spike protein. Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Dunnett’s test. n.s. indicates not significant. The mean values of at least three independent experiments are shown. The error bars denote SD.
    Hek 293t Ace2 Cells, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+hek293+recombinant+cell+line/ACE2+-+HEK293+Recombinant+Cell+Line/pm38466130__nl3c04430_si_001-51-1-15
    Average 94 stars, based on 1 article reviews
    hek 293t ace2 cells - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    ace2 hek293 cell line  (BPS Bioscience)
    94
    BPS Bioscience ace2 hek293 cell line
    DMA-β-CyD acts directly on SARS-CoV-2 and reduces its infectivity titer. DMA-β-CyD was directly exposed to different SARS-CoV-2 variants for ( A ) 10 min and ( B ) 180 min. Viral infectivity titers were expressed in TCID 50 /mL, and significant differences (Student’s t -test) are indicated in the figures. Mean values from at least three independent experiments are shown, and error bars indicate SD. ( C ) Competitive inhibition experiment with DMA-β-CyD. Recombinant <t>ACE2</t> was used, and DMA-β-CyD was pre-incubated before the loading of the recombinant spike protein. Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Dunnett’s test. n.s. indicates not significant. The mean values of at least three independent experiments are shown. The error bars denote SD.
    Ace2 Hek293 Cell Line, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+hek293+recombinant+cell+line/ACE2+-+HEK293+Recombinant+Cell+Line/us11951174-147-1-4
    Average 94 stars, based on 1 article reviews
    ace2 hek293 cell line - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    ace2 hek293 cells  (BPS Bioscience)
    94
    BPS Bioscience ace2 hek293 cells
    DMA-β-CyD acts directly on SARS-CoV-2 and reduces its infectivity titer. DMA-β-CyD was directly exposed to different SARS-CoV-2 variants for ( A ) 10 min and ( B ) 180 min. Viral infectivity titers were expressed in TCID 50 /mL, and significant differences (Student’s t -test) are indicated in the figures. Mean values from at least three independent experiments are shown, and error bars indicate SD. ( C ) Competitive inhibition experiment with DMA-β-CyD. Recombinant <t>ACE2</t> was used, and DMA-β-CyD was pre-incubated before the loading of the recombinant spike protein. Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Dunnett’s test. n.s. indicates not significant. The mean values of at least three independent experiments are shown. The error bars denote SD.
    Ace2 Hek293 Cells, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+hek293+recombinant+cell+line/ACE2+-+HEK293+Recombinant+Cell+Line/pm38381620-290-13-16
    Average 94 stars, based on 1 article reviews
    ace2 hek293 cells - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    DMA-β-CyD acts directly on SARS-CoV-2 and reduces its infectivity titer. DMA-β-CyD was directly exposed to different SARS-CoV-2 variants for ( A ) 10 min and ( B ) 180 min. Viral infectivity titers were expressed in TCID 50 /mL, and significant differences (Student’s t -test) are indicated in the figures. Mean values from at least three independent experiments are shown, and error bars indicate SD. ( C ) Competitive inhibition experiment with DMA-β-CyD. Recombinant ACE2 was used, and DMA-β-CyD was pre-incubated before the loading of the recombinant spike protein. Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Dunnett’s test. n.s. indicates not significant. The mean values of at least three independent experiments are shown. The error bars denote SD.

    Journal: Journal of Virology

    Article Title: Targeting envelope lipids with 2,6‑di‑ O ‑methyl‑3‑acetyl‑β‑cyclodextrin impairs infectivity of SARS‑CoV‑2 and Japanese encephalitis virus

    doi: 10.1128/jvi.01357-25

    Figure Lengend Snippet: DMA-β-CyD acts directly on SARS-CoV-2 and reduces its infectivity titer. DMA-β-CyD was directly exposed to different SARS-CoV-2 variants for ( A ) 10 min and ( B ) 180 min. Viral infectivity titers were expressed in TCID 50 /mL, and significant differences (Student’s t -test) are indicated in the figures. Mean values from at least three independent experiments are shown, and error bars indicate SD. ( C ) Competitive inhibition experiment with DMA-β-CyD. Recombinant ACE2 was used, and DMA-β-CyD was pre-incubated before the loading of the recombinant spike protein. Statistical significance was calculated using one-way analysis of variance (ANOVA) followed by Dunnett’s test. n.s. indicates not significant. The mean values of at least three independent experiments are shown. The error bars denote SD.

    Article Snippet: To determine whether DMA-β-CyD inhibits the binding of the SARS-CoV-2 spike protein to ACE2, an ACE2:SARS-CoV-2 Spike S1 Inhibitor Screening Assay Kit (BPS Bioscience, Inc.) was used.

    Techniques: Infection, Inhibition, Recombinant, Incubation

    DMA-β-CyD prolongs the virus-induced reduction in clotting time in human serum by masking aminophospholipids in the viral lipid envelope. ( A ) The Wuhan, Beta, and Delta variants prepared in Vero E6/TMPRSS2 cells were treated with DMA-β-CyD for the indicated times, followed by a clotting assay. ( B ) The Wuhan variant, prepared in A549 cells overexpressing ACE2, was treated with DMA-β-CyD for the indicated times, followed by a clotting assay. ( C ) To examine the significance of the molecular encapsulation activity of DMA-β-CyD, pretreatment with 10 mM DMAβCyD with equimolar (10 mM) 1adamantanecarboxylic acid was performed to assess its effect on the virus-induced reduction in clotting time. ( D ) The Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with DM-β-CyD for the indicated times, followed by a clotting assay. P values were determined using one-way ANOVA (Dunnett’s test). * indicates a statistically significant difference in clotting time between groups untreated and treated with DMA-β-CyD or DM-β-CyD ( P < 0.05). Data represent the means of at least three independent experiments, and error bars indicate SD.

    Journal: Journal of Virology

    Article Title: Targeting envelope lipids with 2,6‑di‑ O ‑methyl‑3‑acetyl‑β‑cyclodextrin impairs infectivity of SARS‑CoV‑2 and Japanese encephalitis virus

    doi: 10.1128/jvi.01357-25

    Figure Lengend Snippet: DMA-β-CyD prolongs the virus-induced reduction in clotting time in human serum by masking aminophospholipids in the viral lipid envelope. ( A ) The Wuhan, Beta, and Delta variants prepared in Vero E6/TMPRSS2 cells were treated with DMA-β-CyD for the indicated times, followed by a clotting assay. ( B ) The Wuhan variant, prepared in A549 cells overexpressing ACE2, was treated with DMA-β-CyD for the indicated times, followed by a clotting assay. ( C ) To examine the significance of the molecular encapsulation activity of DMA-β-CyD, pretreatment with 10 mM DMAβCyD with equimolar (10 mM) 1adamantanecarboxylic acid was performed to assess its effect on the virus-induced reduction in clotting time. ( D ) The Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with DM-β-CyD for the indicated times, followed by a clotting assay. P values were determined using one-way ANOVA (Dunnett’s test). * indicates a statistically significant difference in clotting time between groups untreated and treated with DMA-β-CyD or DM-β-CyD ( P < 0.05). Data represent the means of at least three independent experiments, and error bars indicate SD.

    Article Snippet: To determine whether DMA-β-CyD inhibits the binding of the SARS-CoV-2 spike protein to ACE2, an ACE2:SARS-CoV-2 Spike S1 Inhibitor Screening Assay Kit (BPS Bioscience, Inc.) was used.

    Techniques: Virus, Coagulation, Variant Assay, Encapsulation, Activity Assay

    Inhibition of viral entry by DMA-β-CyD and evaluation of viral particle stability. ( A ) DMA-β-CyD was preincubated with the SARS-CoV-2 Wuhan variant, which was prepared in Vero E6/TMPRSS2 cells. Free DMA-β-CyD was removed by gel filtration, and the resulting viral particles were then used to infect cells. Four hours after infection, total RNA was extracted from Vero E6/TMPRSS2 cells, and gRNA was detected by RT-PCR. P values were determined by one-way ANOVA using Dunnett’s test (** P < 0.01). N.D. indicates that the SARS-CoV-2 phenotypic RNA (gRNA) was not detected. Data represent the means of at least three independent experiments, and error bars indicate SD. ( B ) DMA-β-CyD was preincubated with the SARS-CoV-2 Wuhan variant, which was prepared in A549 cells overexpressing ACE2. The efficiency of viral entry was similarly examined. Western blot analysis results, shown in the bar graph inset, confirm ACE2 expression in A549 cells. ( C ) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with anti-SARS-CoV-2 patient serum or DMA-β-CyD for 180 min, followed by virus purification by ultracentrifugation and western blot analysis using patient antiserum. ( D ) Evaluation of virus particle stability. (Left panel) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with an anti-S2 antibody and then subjected to gel filtration. Gel filtration was also performed using mouse IgG and IgM as molecular weight markers. The resulting flow-through fraction was analyzed by western blot analysis. (Right panel) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with DMA-β-CyD or anti-SARS-CoV-2 serum. The virus was purified by gel filtration, captured on a plate coated with anti-RBD antibodies, and the number of plate-bound viral particles was quantified by RT-qPCR. P values were determined by one-way ANOVA using Dunnett’s test (** P < 0.01). N.D. indicates that no detectable SARS-CoV-2 gRNA was found. Data represent the means of at least three independent experiments, and error bars indicate SD.

    Journal: Journal of Virology

    Article Title: Targeting envelope lipids with 2,6‑di‑ O ‑methyl‑3‑acetyl‑β‑cyclodextrin impairs infectivity of SARS‑CoV‑2 and Japanese encephalitis virus

    doi: 10.1128/jvi.01357-25

    Figure Lengend Snippet: Inhibition of viral entry by DMA-β-CyD and evaluation of viral particle stability. ( A ) DMA-β-CyD was preincubated with the SARS-CoV-2 Wuhan variant, which was prepared in Vero E6/TMPRSS2 cells. Free DMA-β-CyD was removed by gel filtration, and the resulting viral particles were then used to infect cells. Four hours after infection, total RNA was extracted from Vero E6/TMPRSS2 cells, and gRNA was detected by RT-PCR. P values were determined by one-way ANOVA using Dunnett’s test (** P < 0.01). N.D. indicates that the SARS-CoV-2 phenotypic RNA (gRNA) was not detected. Data represent the means of at least three independent experiments, and error bars indicate SD. ( B ) DMA-β-CyD was preincubated with the SARS-CoV-2 Wuhan variant, which was prepared in A549 cells overexpressing ACE2. The efficiency of viral entry was similarly examined. Western blot analysis results, shown in the bar graph inset, confirm ACE2 expression in A549 cells. ( C ) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with anti-SARS-CoV-2 patient serum or DMA-β-CyD for 180 min, followed by virus purification by ultracentrifugation and western blot analysis using patient antiserum. ( D ) Evaluation of virus particle stability. (Left panel) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with an anti-S2 antibody and then subjected to gel filtration. Gel filtration was also performed using mouse IgG and IgM as molecular weight markers. The resulting flow-through fraction was analyzed by western blot analysis. (Right panel) The SARS-CoV-2 Wuhan variant, prepared in Vero E6/TMPRSS2 cells, was treated with DMA-β-CyD or anti-SARS-CoV-2 serum. The virus was purified by gel filtration, captured on a plate coated with anti-RBD antibodies, and the number of plate-bound viral particles was quantified by RT-qPCR. P values were determined by one-way ANOVA using Dunnett’s test (** P < 0.01). N.D. indicates that no detectable SARS-CoV-2 gRNA was found. Data represent the means of at least three independent experiments, and error bars indicate SD.

    Article Snippet: To determine whether DMA-β-CyD inhibits the binding of the SARS-CoV-2 spike protein to ACE2, an ACE2:SARS-CoV-2 Spike S1 Inhibitor Screening Assay Kit (BPS Bioscience, Inc.) was used.

    Techniques: Inhibition, Variant Assay, Filtration, Infection, Reverse Transcription Polymerase Chain Reaction, Western Blot, Expressing, Virus, Purification, Molecular Weight, Quantitative RT-PCR